NCT01825902 - 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

November 23, 2015

Conditions

Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)Ewing Sarcoma of BoneExtraosseous Ewing SarcomaLocalized Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorUntreated Childhood Supratentorial Primitive Neuroectodermal Tumor

Interventions

DRUG

fluorine F 18 fluorothymidine

Undergo 18F-FLT PET

RADIATION

fludeoxyglucose F 18

Undergo 18F-FDG PET

PROCEDURE

positron emission tomography

Undergo 18F-FLT PET and 18F-FDG PET

PROCEDURE

diffusion-weighted magnetic resonance imaging

Undergo DW-MRI

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester